|
|
 |
|
Viewing report
|
|
|
|
ALK-Abello AS
MarketLine, Dec 2011, Pages: 36
ALK-Abello AS - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.
Features:
- Detailed information on ALK-Abello AS required for business and competitor intelligence needs
- A study of the major internal and external factors affecting ALK-Abello AS in the form of a SWOT analysis
- An in-depth view of the business model of ALK-Abello AS including a breakdown and examination of key business segments
- Intelligence on ALK-Abello AS’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about ALK-Abello AS, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
ALK-Abello (ALK) is a Denmark-based pharmaceutical group engaged in the development and marketing of allergy treatment. The group is focused on allergy vaccination. Its product portfolio includes allergy diagnosis products, such as skin prick tests, immunotherapy tablets and subcutaneous immunotherapy vaccination as well as products for allergy emergency treatment, such as auto-injectors containing adrenalin. ALK primarily operates in Europe. It is headquartered in Horsholm, Denmark, and employed 1,612 people as of December 31, 2010. The group recorded revenues of DKK2,140 million ($381.1 million-) during the financial year (FY) ended December 2010, an increase of 10.6% over FY2009. The operating profit of the group was DKK192 million ($34.2 million-) during FY2010, an increase of 9.7% over FY2009. The net profit was DKK128 million ($22.8 million-) in FY2010, an increase of 8.5% over FY2009. - Calculated using the constant conversion rate of DKK1 = $0.1781 for the financial year ended December 31, 2010.
Reasons to Purchase:
- Gain understanding of ALK-Abello AS and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess ALK-Abello AS as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on ALK-Abello AS’s business structure, strategy and prospects
|
|
|
|
